Remove Chemotherapy Remove Patient Care Remove Vaccines
article thumbnail

Integrating personalised colorectal cancer vaccines into the evolving treatment landscape

Hospital Pharmacy Europe

The idea of cancer vaccines is not new, but Dr Victoria Kunene, consultant medical oncologist at Queen Elizabeth Hospital Birmingham, UK, is leading the charge in their latest iteration: personalised preventative and therapeutic mRNA vaccines against colorectal cancer.

article thumbnail

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Pharmacy Times

1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

Kalis, PharmD, BCOP Key Takeaways Oncology pharmacy's complexity outpaces the generalist model, necessitating specialization for effective patient care and operational efficiency. These are all important and necessary topics that help cancer centers run effectively and deliver exceptional patient care.

article thumbnail

New Online Competency Modules Standardize CPA Pharmacist Training at Academic Medical Center

Pharmacy Times

Their goal was to promote consistent, high-quality, pharmacist-led care by standardizing the way clinical competence is evaluated—both at initial onboarding and as part of ongoing professional development. Using a roadmap strategy, the team established milestones and recruited expert pharmacists involved directly in CPA-driven patient care.

article thumbnail

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

1 "[Meloxicam injection] demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management," Ron Scarboro, chief executive officer at Azurity Pharmaceuticals, said in a press release.

FDA 73
article thumbnail

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

Pharmacy Times

Darkow noted that, unlike a “typical” medication, biologics are larger, and for these reasons, products can encompass a wide range of types of forms, such as certain vaccines, blood products, monoclonal antibodies, cellular therapies, and insulin. Unlike other medications and treatments, they are not chemically synthesized.

article thumbnail

Unpleasant truth: the pandemic, record debt and our opportunity for sustainability

pharmaphorum

Beyond significant cost savings, biosimilar uptake has been shown to simultaneously improve patient access, varying by country. A subsequent change in guidance moved this biologic to a first-line treatment, resulting in an increase in the number of patients who could receive this much-needed treatment by 104%.